In 2023, antihypertensive medicine sales in Canada were estimated at 94 million USD in value, forming the baseline for projected growth. From 2024 to 2028, the market is forecasted to grow steadily from 95.0 to 96.0 million USD. The year-on-year growth rate is modest, at approximately 0.4% annually based on this projection.
The compound annual growth rate (CAGR) over the forecasted period from 2024 to 2028 is around 0.26%. Although the growth is slight, this stability suggests a mature market encountering incremental advancements rather than rapid fluctuations.
Future trends to watch include the development of innovative therapies, potential shifts in government healthcare policies affecting drug pricing, and demographic shifts with an aging population potentially increasing demand. Additionally, monitoring patent expirations and the entry of generic alternatives will be crucial.
